Short-Term Red Wine Consumption Promotes Differential Effects on Plasma Levels of High-Density Lipoprotein Cholesterol, Sympathetic Activity, and Endothelial Function in Hypercholesterolemic, Hypertensive, and Healthy Subjects

OBJECTIVES: To compare the metabolic, hemodynamic, autonomic, and endothelial responses to short-term red wine consumption in subjects with hypercholesterolemia or arterial hypertension, and healthy controls. METHODS: Subjects with hypercholesterolemia (n=10) or arterial hypertension (n=9), or healthy controls (n=7) were given red wine (250 mL/night) for 15 days. Analyses were performed before and after red wine intake. RESULTS: Red wine significantly increased the plasma levels of HDL-cholesterol in the controls, but not in the other groups. The effects on hemodynamic measurements were mild, non-significantly more prominent in healthy subjects, and exhibited high interindividual variability. Across all participants, mean blood pressure decreased 7 mmHg (p <0.01) and systemic vascular resistance decreased 7% (p = 0.05). Heart rate and cardiac output did not significantly change in any group. Red wine enhanced muscle sympathetic fibular nerve activity in hypercholesterolemic and hypertensive patients, but not in controls. At baseline, brachial artery flow-mediated dilation was impaired in patients with hypercholesterolemia and arterial hypertension; red wine restored the dilation in the hypercholesterolemic group but not in the hypertensive group. CONCLUSIONS: Red wine elicits different metabolic, autonomic, and endothelial responses among individuals with hypercholesterolemia or arterial hypertension and healthy controls. Our findings highlight the need to consider patient characteristics when evaluating the response to red wine.(FAPESP) São Paulo Research Foundatio

Bradykinin or Acetylcholine as Vasodilators to Test Endothelial Venous Function in Healthy Subjects

INTRODUCTION: The evaluation of endothelial function has been performed in the arterial bed, but recently evaluation within the venous system has also been explored. Endothelial function studies employ different drugs that act as endothelium-dependent vasodilatory response inductors. OBJECTIVES: The aim of this study is to compare the endothelium-dependent venous vasodilator response mediated by either acetylcholine or bradykinin in healthy volunteers. METHODS AND RESULTS: Changes in vein diameter after phenylephrine-induced venoconstriction were measured to compare venodilation induced by acetylcholine or bradykinin (linear variable differential transformer dorsal hand vein technique). We studied 23 healthy volunteers; 31% were male, and the subject had a mean age of 33 ± 8 years and a mean body mass index of 23 ± 2 kg/m2. The maximum endothelium-dependent venodilation was similar for both drugs (p = 0.13), as well as the mean responses for each dose of both drugs (r = 0.96). The maximum responses to acetylcholine and bradykinin also had good agreement. CONCLUSION: There were no differences between acetylcholine and bradykinin as venodilators in this endothelial venous function investigation

Prevalence of cardiovascular risk factors among truck drivers in the South of Brazil

Abstract\ud \ud Background\ud Truck drivers work under conditions that predispose them to a high prevalence of risk factors for the development of cardiovascular disease (CVD); however, these factors have not been fully evaluated and are not usually considered to be within the scope of health or labor services.\ud \ud \ud Methods\ud An observational cross-sectional study was conducted on 250 long-distance truck drivers; the drivers were all male and were aged 18-60 years. The clinical evaluation consisted of an assessment of social habits and demographic data and an evaluation of risk factors for CVD at 3 time points separated by a one-week interval. To assess the associations with risk factors were used univariate and multivariate analysis. The suitability of the final model fit was assessed via the Hosmer-Lemeshow test. The significance level was set at 5%.\ud \ud \ud Results\ud Among all of the subjects, the prevalence of physical inactivity was 72.8%; consumption of alcoholic beverages, 66.8%; routine use of some type of stimulant during work activities, 19.2%; and smoking, 29%. Only 20.8% had a healthy weight, and 58.2% had an abdominal circumference greater than 102 cm. A diagnosis of arterial hypertension was confirmed in 45.2%, and abnormal glucose levels were detected in 16.4%. Although some of the truck drivers were aware of these conditions, most were not taking specific medications. The logistic regression analysis shows that the odds of hypertension and abnormal glucose levels were increased in truck drivers with abdominal obesity. Age and the family history of premature CVD also increased the chances of hypertension and the abnormal blood glucose levels were related to II or III grade obesity.\ud \ud \ud Conclusion\ud Long-distance truck drivers showed a high prevalence of a cluster of cardiovascular risk factors; these risk factors make the drivers highly susceptible to the development of CVD. The associated risk factors, low compliance with drug treatment, and unique features of this profession suggest that traditional precautions are not sufficient to change this scenario.We acknowledge FAPESP and CNPq for providing grants to Fernanda M\ud Consolim-Colombo. We also thank the Agraria Cooperative by providing\ud room for evaluation of truck drivers

Diretriz Brasileira sobre a Saúde Cardiovascular no Climatério e na Menopausa – 2024

Women, who represent approximately half of the global population according to estimates as of January 2024, may experience signs and symptoms of menopause for at least one-third of their lives, during which they have a higher risk of cardiovascular morbidity and mortality. The effects of menopausal hormone therapy (MHT) on the progression of atherosclerosis and cardiovascular disease (CVD) events vary depending on the age at which MHT is initiated and the time since menopause until its initiation. Beneficial effects on CVD outcomes and all-cause mortality have been observed when MHT was initiated before the age of 60 or within 10 years after menopause. The decision regarding the initiation, dose, regimen, and duration of MHT should be made individually after discussing the benefits and risks with each patient. For primary prevention of postmenopausal chronic conditions, the combined use of estrogen and progestogen is not recommended in asymptomatic women, nor is the use of estrogen alone in hysterectomized women. Hormone-dependent neoplasms contraindicate MHT. For the treatment of genitourinary syndrome of menopause, vaginal estrogen therapy may be used in patients with known cardiovascular risk factors or established CVD. For women with contraindications to MHT or who refuse it, non-hormonal therapies with proven efficacy (antidepressants, gabapentin, and fezolinetant) may improve vasomotor symptoms. Compounded hormonal implants, or "bioidentical" and "compounded" hormones, and "hormone modulation" are not recommended due to lack of scientific evidence of their effectiveness and safety.Mujeres, que representan aproximadamente la mitad de la población mundial según estimaciones de enero de 2024, pueden experimentar signos y síntomas de la menopausia durante al menos un tercio de sus vidas, durante los cuales tienen un mayor riesgo de morbilidad y mortalidad cardiovascular. Los efectos de la terapia hormonal de la menopausia (THM) en la progresión de la aterosclerosis y los eventos de enfermedad cardiovascular (ECV) varían según la edad en que se inicia la THM y el tiempo transcurrido desde la menopausia hasta su inicio. Se han observado efectos beneficiosos en los resultados de ECV y la mortalidad por todas las causas cuando la THM se inició antes de los 60 años o dentro de los 10 años posteriores a la menopausia. La decisión sobre la iniciación, dosis, régimen y duración de la THM debe tomarse individualmente después de discutir los beneficios y riesgos con cada paciente. Para la prevención primaria de condiciones crónicas en la posmenopausia, no se recomienda el uso combinado de estrógeno y progestágeno en mujeres asintomáticas, ni el uso de estrógeno solo en mujeres histerectomizadas. Las neoplasias dependientes de hormonas contraindican la THM. Para el tratamiento del síndrome genitourinario de la menopausia, se puede usar terapia estrogénica vaginal en pacientes con factores de riesgo cardiovascular conocidos o ECV establecida. Para mujeres con contraindicaciones a la THM o que la rechazan, las terapias no hormonales con eficacia demostrada (antidepresivos, gabapentina y fezolinetant) pueden mejorar los síntomas vasomotores. Los implantes hormonales compuestos, o hormonas "bioidénticas" y "compuestas", y la "modulación hormonal" no se recomiendan debido a la falta de evidencia científica sobre su efectividad y seguridad.As mulheres, que representam cerca de metade da população mundial segundo estimativas de janeiro de 2024, podem sofrer com sinais e sintomas da menopausa durante pelo menos um terço de suas vidas, quando apresentam maiores risco e morbimortalidade cardiovasculares. Os efeitos da terapia hormonal da menopausa (THM) na progressão de eventos de aterosclerose e doença cardiovascular (DCV) variam de acordo com a idade em que a THM é iniciada e o tempo desde a menopausa até esse início. Efeitos benéficos nos resultados de DCV e na mortalidade por todas as causas ocorreram quando a THM foi iniciada antes dos 60 anos de idade ou nos 10 anos que se seguiram à menopausa. A decisão sobre o início, a dose, o regime e a duração da THM deve ser tomada individualmente após discussão sobre benefícios e riscos com cada paciente. Para a prevenção primária de condições crônicas na pós-menopausa, não se recomendam o uso combinado de estrogênio e progestagênio em mulheres assintomáticas nem o uso de estrogênio sozinho em mulheres histerectomizadas. Neoplasias hormônio-dependentes contraindicam a THM. Para tratamento da síndrome geniturinária da menopausa, pode-se utilizar terapia estrogênica por via vaginal em pacientes com fatores de risco cardiovascular conhecidos ou DCV estabelecida. Para mulheres com contraindicação à THM ou que a recusam, terapias não hormonais com eficácia comprovada (antidepressivos, gabapentina e fezolinetante) podem melhorar os sintomas vasomotores. Os implantes hormonais manipulados, ou hormônios “bioidênticos” “manipulados”, e a ‘modulação hormonal’ não são recomendados pela falta de evidência científica de sua eficácia e segurança

Repercussão funcional da disfunção endotelial venosa em hipertensos - correlação entre função endotelial e variáveis hemodinámica

Enquanto há inúmeros trabalhos evidenciando a participação do território arterial na fisiopatologia da Hipertensão Arterial Sistêmica (HAS), pouco ainda se conhece da real participação do território venoso nessa doença. Neste protocolo foram avaliados 27 indivíduos do Grupo Controle (GC) e 31 pacientes do Grupo Hipertenso (GH). Curvas de pressão arterial (PA) foram obtidas de forma não invasiva com o Finometer®, durante 10 minutos de repouso na posição supina (basal) e durante 10 minutos em manobra de modulação de volume (Tilt test). Por meio da análise das curvas foram calculadas variáveis hemodinâmicas. Concluiu-se que, na população de hipertensos estudada, há uma coexistência entre disfunção endotelial venosa e menor complacência venosa, porém não ficou evidenciada a correlação entre a disfunção endotelial venosa, a capacitância venosa, a complacência venosa e as variáveis de padrão hemodinâmico

Estrés oxidativo y disfunción endotelial en la enfermedad renal crónica

FUNDAMENTO: A doença renal crônica (DRC) caracteriza-se pela alta prevalência de aterosclerose. Uma vez que o estresse oxidativo e a disfunção endotelial são promotores da aterosclerose, é interessante verificar se as duas condições estão associadas em pacientes com DRC, ainda sem doença cardiovascular (DCV) clínica. OBJETIVO: Avaliar as relações entre o estresse oxidativo e a função endotelial em pacientes com DRC estágio 5, sem DCV. MÉTODOS: Foram estudados 22 pacientes com DRC, não-diabéticos, não-fumantes, sem DCV e tratados por hemodiálise; além de 22 indivíduos normais. Em todos os indivíduos foram avaliados a reatividade vascular, dependente e independente de endotélio (ultra-som de alta resolução da artéria braquial), e o estresse oxidativo (níveis plasmáticos de substâncias reativas ao ácido tiobarbitúrico - TBARS). RESULTADOS: A reatividade vascular dependente de endotélio (6,0 ± 4,25% vs. 11,3 ± 4,46%, p <0,001) e a reatividade independente de endotélio (11,9 ± 7,68% vs. 19,1 ± 6,43%, p <0,001) foram reduzidas na DRC, enquanto o estresse oxidativo (2,63 ± 0,51 vs. 1,49 ± 0,43, p <0,001) foi aumentado. Os níveis de TBARS, quando utilizado na totalidade de indivíduos do estudo (pacientes e controles), correlacionaram-se com a reatividade vascular dependente de endotélio (r = -0,56, p<0,001) e com a pressão arterial sistólica (r = 0,48, p = 0,002). CONCLUSÃO: O estresse oxidativo é associado à disfunção endotelial. Pacientes com DRC apresentam aumento do estresse oxidativo e comprometimento da reatividade vascular. Os resultados sugerem ainda que o estresse oxidativo e a disfunção endotelial podem estar envolvidos na susceptibilidade exagerada da DRC às complicações cardiovasculares.BACKGROUND: Chronic kidney disease (CKD) is characterized by the high prevalence of atherosclerosis. Considering that endothelial dysfunction and oxidative stress are promoters of atherosclerosis, it is of interest to verify whether the two conditions are associated in CKD patients still free of clinical cardiovascular disease (CVD). OBJECTIVE: To evaluate the association between oxidative stress and endothelial function in end-stage CKD patients without clinically evident CVD. METHODS: We studied 22 nondiabetic, nonsmoker CKD patients without clinical CVD treated by maintenance hemodialysis and 22 healthy controls. Endothelium- dependent and independent vascular reactivity and oxidative stress, as determined by the plasma levels of thiobarbituric acid-reactive substances - TBARS, were evaluated in all subjects. RESULTS: Endothelium-dependent (6.0 ± 4.25 vs. 11.3 ± 4.46 %, p< 0.001) and endothelium-independent (11.9 ± 7.68 vs. 19.1 % ± 6.43 %, p< 0.001) vascular reactivity were reduced, while TBARS (2.63 ± 0.51 vs. 1.49 ± 0.42 nmols/mL) was increased in CKD patients when compared to controls. TBARS levels were significantly related to endothelium-dependent vascular reactivity (r= - 0.56, p< 0.001) and to systolic blood pressure (r= - 0.48, p= 0.002). CONCLUSION: Oxidative stress is increased in CKD patients free of CVD and is associated with endothelial dysfunction in patients and controls. The results suggest that oxidative stress and endothelial dysfunction may be involved in the increased susceptibility of CKD patients to CVD and cardiovascular complications.FUNDAMENTO: La enfermedad renal crónica (ERC) se caracteriza por la alta prevalencia de aterosclerosis Siendo el estrés oxidativo y la disfunción endotelial promotores de la aterosclerosis, es interesante verificar si las dos condiciones están asociadas en pacientes con ERC, aun sin enfermedad cardiovascular (ECV) clínica. OBJETIVO: Evaluar las relaciones entre el estrés oxidativo y la función endotelial en pacientes con ERC estado 5, sin ECV. MÉTODOS: Se estudiaron 22 pacientes con ERC, no diabéticos, no fumadores, sin ECV y tratados por hemodiálisis; además de 22 individuos normales. En todos los individuos se evaluaron la reactividad vascular, dependiente e independiente de endotelio (ecografía de alta resolución de la arteria braquial), y el estrés oxidativo (niveles plasmáticos de sustancias reactivas al ácido tiobarbitúrico - TBARS). RESULTADOS: La reactividad vascular dependiente de endotelio (6,0 ± 4,25% vs. 11,3 ± 4,46%, p <0,001) y la reactividad independiente de endotelio (11,9 ± 7,68% vs. 19,1 ± 6,43%, p <0,001) se redujeron en la ERC, mientras el estrés oxidativo (2,63 ± 0,51 vs. 1,49 ± 0,43, p <0,001) se vio aumentado. Los niveles de TBARS, cuando se utiliza en la totalidad de individuos del estudio (pacientes y controles), se correlacionaron con la reactividad vascular dependiente de endotelio (r = -0,56, p<0,001) y con la presión arterial sistólica (r = 0,48, p = 0,002). CONCLUSIÓN: El estrés oxidativo está asociado a la disfunción endotelial. Pacientes con ERC presentan aumento del estrés oxidativo y compromiso de la reactividad vascular. Los resultados sugieren además que el estrés oxidativo y la disfunción endotelial pueden estar involucrados en la susceptibilidad exagerada de la ERC a las complicaciones cardiovasculares